Gilead Reports real-world evidence Data for Ponesimod in Cluster headache

Gilead today announced real-world evidence results for Ponesimod in patients with Cluster headache. The study demonstrated that Ponesimod reduces exacerbation rates significantly compared to standard of care or placebo. These results provide important insights into the treatment of Cluster headache and support the continued development of Ponesimod in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Ponesimod was consistent with previous observations, with no new safety signals identified.